Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.AORT · Entity 4767 | Director | May 18, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date May 18, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,223 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 7,576 · Balance 76,223 F1: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 21, 2026 00:30 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-036999 · wk-form4_1779323410.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,223 F1 · shares: RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:08 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 6,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000103 · wk-form4_1748376476.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,647 F1 · shares: RSA Grant vests on May 22, 2026, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 12:36 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 6,289 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000197 · wk-form4_1717418172.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,322 F1 · shares: RSA Grant vests on May 30th 2025, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:49 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 9,709 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-23-000112 · wk-form4_1686260970.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,033 F1 · balance_after: RSA Grant vests on June 6th 2024, pursuant to the terms of the Equity and Cash Incentive Plan? Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:39 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 7,878 | $19.04 | $149,997.12 |
DisclosureSEC source: 0000784199-22-000144 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,324 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2023, provided the status as a Director with Artivion continues through such date. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:22 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,423 | $29.39 | $129,991.97 |
DisclosureSEC source: 0000784199-21-000169 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,446 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2022, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:50 UTC | ARTIVION, INC. CRY · Entity 4767 | PurchaseCommon Stock | 10,000 | $16.63 | $166,273.00 |
DisclosureSEC source: 0000784199-20-000192 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,023 F1 · price: Reflects the average weighted price of $16.6273 the shares were purchased. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at this price. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:44 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 5,667 | $22.94 | $130,000.98 |
DisclosureSEC source: 0000784199-20-000159 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,023 F1 · shares: Represents shares of restricted stock that cliff vest on June 1, 2021, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:18 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 1,289 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000105 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,356 F1 · shares: RSA Covid grant vests on May 4, 2021, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:21 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,163 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-19-000114 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,067 F1 · shares: Represents shares of restricted stock that cliff vest on May 16, 2020, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:15 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,638 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-18-000111 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,904 F1 · shares: Represents shares of restricted stock that cliff vest on May 23, 2019, provided the status as a Director with CryoLife continues through such date. Read SEC document |
| May 17, 2017 Filed May 18, 2017 20:33 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 5,263 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-17-000051 · certent-form4.xml · nonDerivative · entry 1 Bullock James · CIK 0001172340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,266 F1 · shares: Represents shares of restricted stock that vest on the first anniversary of the grant date if the reporting person remains a member of the Company's board of directors, subject to earlier vesting upon certain events including death, disability and retirement from the board after serving out his full term because the director is not standing for re-election at the end of the term. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.